Ilumya market growth accelerates as psoriasis treatments expand

The Business Research Company says the global Ilumya market is gaining momentum, driven by rising psoriasis cases, higher healthcare spending and more investment in clinical trials. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - The Ilumya market is tied to the expanding treatment needs of adults with moderate to severe plaque psoriasis. - Growth in biologic dermatology could boost demand for long-acting therapies with more convenient dosing and broader access. - Market expansion may affect drug development, prescribing patterns and payer coverage for psoriasis care.

What happened: - The Business Research Company released its Ilumya Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Nov. 5, 2026. - The report says the Ilumya market is in a rapid growth phase. - The report forecasts continued expansion through 2035. - North America held the largest share of the Ilumya market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - Ilumya is a prescription drug for adults with moderate to severe plaque psoriasis who qualify for systemic therapy or ultraviolet light treatment. - Ilumya is a monoclonal antibody that targets interleukin-23, or IL-23. - Blocking IL-23 reduces inflammation and slows excess skin cell production tied to psoriasis. - The report links past growth to limits in topical psoriasis treatments, rising chronic plaque psoriasis cases, early approval of biologic dermatology drugs, strong dermatologist adoption of biologics and patient demand for durable skin clearance. - Future growth is expected to come from wider use of biologic therapies in dermatology, growth in systemic psoriasis treatments, broader insurance coverage, advances in cytokine-selective therapies and stronger patient adherence programs. - The report identifies increased use of IL-23 inhibitors, longer-acting psoriasis therapies, stronger demand for biologic dermatology treatments, better dosing convenience and more care options for moderate to severe psoriasis as key trends. - Psoriasis prevalence is a major driver because the disorder causes accelerated skin cell growth that leads to red, scaly patches. - The report points to improved diagnosis, greater awareness, environmental factors, genetics, obesity and some medications and infections as drivers of rising psoriasis incidence. - A May 2023 National Library of Medicine report projected higher psoriasis incidence and disability-adjusted life years among people ages 30 to 39 through 2030. - Rising healthcare spending is also supporting demand for advanced psoriasis treatments, including biologics such as Ilumya. - The UK Office for National Statistics said total healthcare expenditure rose 5.6% in nominal terms from 2022 to 2023, compared with 0.9% growth the year before. - More clinical trial funding is helping support research into biologic therapies for chronic inflammatory diseases like psoriasis. - The Association of the British Pharmaceutical Industry said UK industry-sponsored clinical trials increased from 411 in 2022 to 426 in 2023.

Between the lines: - The report frames Ilumya as part of a broader shift toward targeted biologics in dermatology. - Payer coverage and adherence support may matter as much as drug efficacy because both can shape real-world uptake. - Regional growth patterns suggest the market is still concentrated in mature healthcare systems, but demand is widening beyond North America.

What's next: - The report points to deeper penetration of biologic therapies, which could expand Ilumya use if access and reimbursement improve. - Faster growth in Asia-Pacific could shift the center of market opportunity over the forecast period. - The company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and updated technology and trend analysis. - More information is available in the full report and a free sample.